Testicular germ cell tumor (GCT) · line 1 · EP (etoposide + cisplatin, germ cell tumor)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 1 |
|---|---|
| Track | standard |
| Linked regimen | REG-EP-GCT |
| ID | IND-GCT-METASTATIC-1L-EP |
|---|---|
| Type | Indication |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | DIS-TESTICULAR-GCT |
| Sources | SRC-IGCCC-1997 SRC-NCCN-TESTICULAR-2025 |
Notes
Historical note: the prior Loehrer citation carried an invalid PMID and was not retained as a formal source. EP × 4 / BEP × 3 comparative context is cited via SRC-NCCN-TESTICULAR-2025; the historical primary comparison needs qualified bibliographic verification before claim-level mapping.
Used By
Algorithms
ALGO-GCT-METASTATIC-1L- ALGO-GCT-METASTATIC-1L
Indication
IND-GCT-METASTATIC-1L-BEP- IND-GCT-METASTATIC-1L-BEP